Pill-in-the-Pocket Strategy — EECC MCQ

Correct answer: A — Co-prescribe an AV-nodal rate-limiting agent

Flecainide (a class IC antiarrhythmic) can organise AF into atrial flutter with a slower atrial rate that may conduct 1:1 through the AV node, causing haemodynamically unstable rapid ventricular rates. To prevent this, a rate-limiting agent (beta-blocker or non-DHP calcium channel blocker) must be co-prescribed. The 'pill-in-the-pocket' strategy (single-dose oral flecainide 200-300 mg taken by the patient at symptom onset) is recommended for self-termination of infrequent, well-tolerated paroxysmal AF in patients without structural heart disease. The first dose should be administered under medical supervision. Flecainide is contraindicated in structural heart disease, ischaemic heart disease, and HFrEF. Apply this conclusion only to the clinical circumstances stated, with appropriate specialist review, contraindication checks, shared decision-making and follow-up. Reassess if the physiology, treatment response or competing risk changes. The competing options would require a different haemodynamic profile, diagnosis, procedural indication or risk balance from the one described here.

Reference: ESC (2024): Guidelines for the Management of Atrial Fibrillation: https://bnf.nice.org.uk/